1. Home
  2. XMAX vs ARVN Comparison

XMAX vs ARVN Comparison

Compare XMAX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XMAX Inc. Common Stock

XMAX

XMAX Inc. Common Stock

SELL

Current Price

$5.85

Market Cap

529.8M

ML Signal

SELL

Logo Arvinas Inc.

ARVN

Arvinas Inc.

SELL

Current Price

$6.74

Market Cap

600.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
XMAX
ARVN
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.8M
600.2M
IPO Year
2009
2018

Fundamental Metrics

Financial Performance
Metric
XMAX
ARVN
Price
$5.85
$6.74
Analyst Decision
Buy
Analyst Count
0
15
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
★ 1.2M
879.9K
Earning Date
11-13-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 88.51
58.84
EPS
0.42
★ 0.88
Revenue
$12,744,871.00
★ $262,600,000.00
Revenue This Year
N/A
$5.67
Revenue Next Year
N/A
N/A
P/E Ratio
$14.42
★ $7.69
Revenue Growth
N/A
★ N/A
52 Week Low
$3.03
$6.33
52 Week High
$9.40
$14.20

Technical Indicators

Market Signals
Indicator
XMAX
ARVN
Relative Strength Index (RSI) 40.97 39.01
Support Level $3.03 $6.54
Resistance Level $9.16 $7.85
Average True Range (ATR) 0.97 0.46
MACD 0.06 -0.03
Stochastic Oscillator 53.49 15.88

Price Performance

Historical Comparison
XMAX
ARVN

About XMAX XMAX Inc. Common Stock

XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: